McCarty, Todd P.

Invasive Candidiasis

McCarty, T. P., & Pappas, P. G. (2016) · Infectious Disease Clinics of North America

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 285

Candidemia and Invasive Candidiasis

McCarty, T. P., White, C. M., & Pappas, P. G. (2021) · Infectious Disease Clinics of North America

Antifungal resistance and susceptibilityInfective Endocarditis Diagnosis and Management

Cited by 260

Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial

Thompson, G. R., Soriano, A., Cornely, O. A., Kullberg, B. J., Kollef, M., Vazquez, J., Honore, P. M., Bassetti, M., Pullman, J., Chayakulkeeree, M., et al. (2023) · The Lancet

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 192

Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial

Pappas, P. G., Vazquez, J. A., Oren, I., Rahav, G., Aoun, M., Bulpa, P., Ben-Ami, R., Ferrer, R., Mccarty, T., Thompson, G. R., et al. (2023) · Journal of Antimicrobial Chemotherapy

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 65

Echinocandin resistance among Candida isolates at an academic medical centre 2005–15: analysis of trends and outcomes

McCarty, T. P., Lockhart, S. R., Moser, S. A., Whiddon, J., Zurko, J., Pham, C. D., & Pappas, P. G. (2018) · Journal of Antimicrobial Chemotherapy

Antifungal resistance and susceptibilityFungal Plant Pathogen Control

Cited by 21

147. Clinical Safety and Efficacy of Novel Antifungal, Fosmanogepix, in the Treatment of Candidemia: Results from a Phase 2 Proof of Concept Trial

Pappas, P., Kullberg, B. J., Vazquez, J. A., Oren, I., Rahav, G., Aoun, M., Bulpa, P., Ben-Ami, R., Ferrer, R., McCarty, T. P., et al. (2020) · Open Forum Infectious Diseases

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 17